Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06904313 · ClinicalTrials.gov registry record · Phase 2
Ultralow Dose PET Imaging for PSMA Expression
A Phase 2 study of Healthy Volunteer and Prostate CA, sponsored by Akiva Mintz.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06904313 is a Phase 2 study of Healthy Volunteer and Prostate CA that is actively recruiting participants, run by Akiva Mintz. The registered enrollment target is 200 participants, roughly in line with the 200-participant average among 112 other Healthy Volunteer trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06904313, a Phase 2 study of Healthy Volunteer and Prostate CA, is actively recruiting participants, sponsored by Akiva Mintz.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Conditions Studied
Interventions
- DRUG Piflufolastat F18
Study Locations (1)
New Jersey
- Nuclear Imaging Institute - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06904313
The ClinicalTrials.gov registry entry for NCT06904313 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 200-participant average among 112 other Healthy Volunteer trials with a reported enrollment target. The listed sponsor is Akiva Mintz, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Volunteer appearing as the primary indexed condition, and to 1 intervention - of which Piflufolastat F18 is the first listed.
NCT06904313 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06904313 about?
NCT06904313 is a clinical study titled "Ultralow Dose PET Imaging for PSMA Expression". The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose...
What is the current status of trial NCT06904313?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-05-12. Estimated completion is 2030-06-30.
What conditions does trial NCT06904313 study?
This clinical trial studies the following conditions: Healthy Volunteer, Prostate CA.
What interventions are being tested in trial NCT06904313?
The interventions under investigation include: Piflufolastat F18 (DRUG).
Who is sponsoring clinical trial NCT06904313?
This trial is sponsored by Akiva Mintz, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06904313 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
RECRUITING · Phase 2
-
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
RECRUITING · Phase 2
-
Ultralow Dose PET Imaging of 18F-FDG Uptake
RECRUITING · Phase 2
-
Ultralow Dose PET Imaging for 18F-NaF Uptake
RECRUITING · Phase 2
-
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
COMPLETED · Phase 2
-
Healthy Volunteer Study
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.